Last reviewed · How we verify

Rectal Indomethacin

Moti Lal Nehru Medical College · FDA-approved active Small molecule Under review Quality 0/100

Rectal Indomethacin is a Nonsteroidal anti-inflammatory drug (NSAID) Small molecule drug developed by Moti Lal Nehru Medical College. It is currently FDA-approved for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis. Also known as: Indocin, NSAIDs, NSAIDS, Indomethacin Suppositories.

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

Rectal Indomethacin is a small molecule that acts as a cyclooxygenase inhibitor. It has been studied in clinical trials for various conditions, including pancreatitis and papillomavirus infections, and is administered via rectal route.

At a glance

Generic nameRectal Indomethacin
Also known asIndocin, NSAIDs, NSAIDS, Indomethacin Suppositories
SponsorMoti Lal Nehru Medical College
Drug classNonsteroidal anti-inflammatory drug (NSAID)
TargetCyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
ModalitySmall molecule
Therapeutic areaRheumatology, Pain Management, Neurology
PhaseFDA-approved

Mechanism of action

Indomethacin blocks both COX-1 and COX-2 enzymes, which are responsible for converting arachidonic acid into prostaglandins. By reducing prostaglandin levels, the drug suppresses inflammatory mediators and provides analgesic and antipyretic effects. The rectal formulation allows for local and systemic absorption, making it useful for patients unable to take oral medication.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Rectal Indomethacin

What is Rectal Indomethacin?

Rectal Indomethacin is a Nonsteroidal anti-inflammatory drug (NSAID) drug developed by Moti Lal Nehru Medical College, indicated for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.

How does Rectal Indomethacin work?

Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.

What is Rectal Indomethacin used for?

Rectal Indomethacin is indicated for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis, Acute pain and inflammation, Patent ductus arteriosus (PDA) closure in premature infants.

Who makes Rectal Indomethacin?

Rectal Indomethacin is developed and marketed by Moti Lal Nehru Medical College (see full Moti Lal Nehru Medical College pipeline at /company/moti-lal-nehru-medical-college).

Is Rectal Indomethacin also known as anything else?

Rectal Indomethacin is also known as Indocin, NSAIDs, NSAIDS, Indomethacin Suppositories.

What drug class is Rectal Indomethacin in?

Rectal Indomethacin belongs to the Nonsteroidal anti-inflammatory drug (NSAID) class. See all Nonsteroidal anti-inflammatory drug (NSAID) drugs at /class/nonsteroidal-anti-inflammatory-drug-nsaid.

What development phase is Rectal Indomethacin in?

Rectal Indomethacin is FDA-approved (marketed).

What are the side effects of Rectal Indomethacin?

Common side effects of Rectal Indomethacin include Gastrointestinal irritation or ulceration, Dyspepsia, Headache, Dizziness, Rectal irritation (rectal formulation), Nausea.

What does Rectal Indomethacin target?

Rectal Indomethacin targets Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) and is a Nonsteroidal anti-inflammatory drug (NSAID).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing